216 related articles for article (PubMed ID: 34252201)
1. Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.
Largent EA; Abera M; Harkins K; Feldman SJ; Uhlmann WR; Roberts JS; Karlawish J;
J Am Geriatr Soc; 2021 Nov; 69(11):3203-3211. PubMed ID: 34252201
[TBL] [Abstract][Full Text] [Related]
2. Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Largent EA; Harkins K; van Dyck CH; Hachey S; Sankar P; Karlawish J
PLoS One; 2020; 15(2):e0229137. PubMed ID: 32053667
[TBL] [Abstract][Full Text] [Related]
3. Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Mozersky J; Sankar P; Harkins K; Hachey S; Karlawish J
JAMA Neurol; 2018 Jan; 75(1):44-50. PubMed ID: 29059270
[TBL] [Abstract][Full Text] [Related]
4. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA
JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558
[TBL] [Abstract][Full Text] [Related]
5. Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Lim YY; Maruff P; Getter C; Snyder PJ
Alzheimers Dement; 2016 Apr; 12(4):454-8. PubMed ID: 26750717
[TBL] [Abstract][Full Text] [Related]
6. Reasons for undergoing amyloid imaging among cognitively unimpaired older adults.
Ryan MM; Gillen DL; Grill JD
Ann Clin Transl Neurol; 2021 Aug; 8(8):1646-1655. PubMed ID: 34227249
[TBL] [Abstract][Full Text] [Related]
7. Disclosing Genetic Risk of Alzheimer's Disease to Cognitively Unimpaired Older Adults: Findings from the Study of Knowledge and Reactions to APOE Testing (SOKRATES II).
Largent EA; Bhardwaj T; Abera M; Stites SD; Harkins K; Lerner AJ; Bradbury AR; Karlawish J
J Alzheimers Dis; 2021; 84(3):1015-1028. PubMed ID: 34602479
[TBL] [Abstract][Full Text] [Related]
8. Research Participants' Perspectives on Precision Diagnostics for Alzheimer's Disease.
Smith HS; Robinson JO; Levchenko A; Pereira S; Pascual B; Bradbury K; Arbones V; Fong J; Shulman JM; McGuire AL; Masdeu J
J Alzheimers Dis; 2024; 97(3):1261-1274. PubMed ID: 38250770
[TBL] [Abstract][Full Text] [Related]
9. Informing Disclosure: Efficacy of a Brief Educational Intervention on Research Participants' Knowledge about Alzheimer's Disease Biomarkers.
Ketchum FB; Erickson CM; Basche KE; Chin NA; Rosario HL; Johnson SC; Clark LR
J Alzheimers Dis; 2023; 96(2):515-522. PubMed ID: 37807783
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
11. Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes.
Erickson CM; Ketchum FB; Basche KE; Chin NA; Eveler ML; Clark LR
Alzheimers Dement (N Y); 2024; 10(2):e12483. PubMed ID: 38882702
[TBL] [Abstract][Full Text] [Related]
12. Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.
Ghisays V; Goradia DD; Protas H; Bauer RJ; Devadas V; Tariot PN; Lowe VJ; Knopman DS; Petersen RC; Jack CR; Caselli RJ; Su Y; Chen K; Reiman EM
Alzheimers Dement; 2020 Apr; 16(4):598-609. PubMed ID: 31831374
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults.
Parra MA; Gazes Y; Habeck C; Stern Y
J Prev Alzheimers Dis; 2024; 11(2):339-347. PubMed ID: 38374740
[TBL] [Abstract][Full Text] [Related]
14. Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data.
Amariglio RE; Sikkes SAM; Marshall GA; Buckley RF; Gatchel JR; Johnson KA; Rentz DM; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge KC; Sims JR; Grill JD; Aisen PS; Sperling RA
J Prev Alzheimers Dis; 2021; 8(3):257-262. PubMed ID: 34101781
[TBL] [Abstract][Full Text] [Related]
15. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
[TBL] [Abstract][Full Text] [Related]
16. Episodic Memory and Learning Dysfunction Over an 18-Month Period in Preclinical and Prodromal Alzheimer's Disease.
Baker JE; Lim YY; Jaeger J; Ames D; Lautenschlager NT; Robertson J; Pietrzak RH; Snyder PJ; Villemagne VL; Rowe CC; Masters CL; Maruff P
J Alzheimers Dis; 2018; 65(3):977-988. PubMed ID: 30103330
[TBL] [Abstract][Full Text] [Related]
17. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
19. "And Does That Necessarily Mean Absolutely Alzheimer's?" An Analysis of Questions Raised Following Amyloid PET Results Disclosure.
Kim JE; Tamres LK; Orbell SL; Cheng RZ; Klunk WE; Aizenstein HJ; Butters MA; McDade E; Lingler JH
Am J Geriatr Psychiatry; 2024 Jan; 32(1):45-54. PubMed ID: 37634955
[TBL] [Abstract][Full Text] [Related]
20. Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.
Grill JD; Cox CG; Harkins K; Karlawish J
Alzheimers Res Ther; 2018 Dec; 10(1):125. PubMed ID: 30579361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
